9. Prophylaxis with rivoroxaban of catheter associated thrombosis in cancer patients (cat-rivo trial): main data and intermediate results of prospective multicenter study

Authors

  • T.K. Tajibayev Казахстанско-Российский Медицинский Университет, г. Алматы, Казахстан, Международный медицинский центр «Private Clinic Almaty», г. Алматы, Казахстан
  • A.A. Baubekov Международный медицинский центр «Private Clinic Almaty», г. Алматы, Казахстан
  • V.M. Madyarov Казахстанско-Российский Медицинский Университет, г. Алматы, Казахстан
  • I.Y. Sagatov АО «Национальный Научный Центр Хирургии им. А.Н. Сызганова», г. Алматы, Казахстан
  • O.Zh. Shulenbayev Международный медицинский центр «Private Clinic Almaty», г. Алматы, Казахстан
  • A.E. Karassayeva Almaty Cancer Center, Almaty, Kazakhstan, Алматинский Онкологический Центр, г. Алматы, Казахстан
  • D.E. Aidarov Казахстанско-Российский Медицинский Университет, г. Алматы, Казахстан, Almaty Cancer Center, Almaty, Kazakhstan, Алматинский Онкологический Центр, г. Алматы, Казахстан
  • A.E. Aidarov Казахстанско-Российский Медицинский Университет, г. Алматы, Казахстан, Almaty Cancer Center, Almaty, Kazakhstan, Алматинский Онкологический Центр, г. Алматы, Казахстан
  • M. Khanchi АО «Национальный Научный Центр Хирургии им. А.Н. Сызганова», г. Алматы, Казахстан
  • A.Ye. Saduakas АО «Национальный Научный Центр Хирургии им. А.Н. Сызганова», г. Алматы, Казахстан

Downloads

Abstract

Central venous catheters (CVCs), such as the tunneled catheters and the totally implanted ports, play a major role in general medicine and oncology. Thrombosis associated with CVCs is a common complication in cancer patients. Thus, in order to more widely study the problem of catheter-associated thrombosis in cancer patients, we initiated a study for 2022-2023 within one region.. Purpose. Evaluation of the efficacy and safety of thromboprophylaxis of catheter-associated thrombosis with rivaroxaban in cancer patients..

Material and methods. Prospective multicenter study, conducted since 01/05/2022 and planned to be completed by the end of 2022, on the basis of three centers. The subjects are divided into 2 groups to randomize 60 participants in each. The first group: receive DOACs (rivaroxaban) at a dosage of 20 mg per day the day before the inserting of the CVC. Second group: treatment of the underlying disease without the use of DOACs..

Results. None of the patients developed submassive or massive pulmonary embolism. There were no cases of CAT in the thromboprophylaxis group compared to the non-thrombotic prophylaxis group (0% vs 15.7%). The relative risk of developing CAT is 0.86, which indicates the effectiveness of thromboprophylaxis with rivaroxaban..

Conclusion. Our interim results show the efficacy of rivaroxaban at a dosage of 20 mg per day in cancer patients. The final results are planned to be published at the end of the study.

Keywords

central venous catheter, CVC, central venous catheter-associated thrombosis, central venous catheter-associated deep vein thrombosis, CAT, catheter-related thrombosis, CRT, culmonary embolism, PE, cancer

References

  1. Laube ES, Mantha S, Samedy P, Wills J, Harnicar S, Soff GA. Treatment of central Murray J, Precious E, Alikhan R. Catheter-related thrombosis in cancer patients. Br J Haematol. 2013 Sep;162(6):748-57
  2. Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. Oncologist. 2004;9(2):207-16. doi:10.1634/theoncologist.9-2-207
  3. Elyamany G, Alzahrani AM, Bukhary E. Cancer-Associated Thrombosis: An Overview. Clinical Medicine Insights: Oncology. 2014;8
  4. Karimi M, Cohan N. Cancer-Associated Thrombosis. The Open Cardiovascular Medicine Journal 2010;4:78–82
  5. Yilmaz KB, Akinci M, Dogan L, Yologlu Z, Atalay C, Kulacoglu H. Central venous catheter-associated thrombosis in the perioperative period: a frequent complication in cancer patients that can be detected early with doppler examination. Tumori. 2010 Sep-Oct;96(5):690-4
  6. Zwicker JI, Connolly G, Carrier M, Kamphuisen PW, Lee AY. Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2014 May;12(5):796-800
  7. Yilmaz KB, Akinci M, Dogan L, Yologlu Z, Atalay C, Kulacoglu H. Central venous catheter-associated thrombosis in the perioperative period: a frequent complication in cancer patients that can be detected early with doppler examination. Tumori. 2010 Sep-Oct;96(5):690-4
  8. Davies GA, Lazo-Langner A, Gandara E, Rodger M, Tagalakis V, Louzada M, Corpuz R, Kovacs MJ. A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2). Thromb Res. 2018 Feb;162:88-92
  9. Levine M, Kakkar AK. Catheter-associated thrombosis: thromboprophylaxis or not? Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005 Jun;23(18):4006-4008
  10. Chan A, Iannucci A, Dager WE. Systemic anticoagulant prophylaxis for central catheter-associated venous thrombosis in cancer patients. Ann Pharmacother. 2007 Apr;41(4):635-41
  11. Laube ES, Mantha S, Samedy P, Wills J, Harnicar S, Soff GA. Treatment of central venous catheter-associated deep venous thrombosis in cancer patients with rivaroxaban. Am J Hematol. 2017 Jan;92(1):E9-E10.

Published

2022-11-22

Issue

No. 4 (2022)

Section

Статьи